Azione NTRP NEUROTROPE, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati
Strumento inattivo

Altre lingue Neurotrope, Inc.

Azioni

NTRP

US64129T2078

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc.
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction.
NEUROTROPE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
NEUROTROPE, INC. : Other Events (form 8-K)
NEUROTROPE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease
NEUROTROPE, INC. : Other Events (form 8-K)
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
NEUROTROPE, INC. : Other Events (form 8-K)
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Neurotrope : Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute Trial for Childhood Leukemia
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1
NEUROTROPE, INC. : Regulation FD Disclosure, Other Events (form 8-K)
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione NTRP
  4. Notizie Neurotrope, Inc.
  5. Altre lingue